Trump Administration Slaps Pharma Industry with International Reference Pricing Rule (But will it Survive?)

Trump Administration Slaps Pharma Industry with International Reference Pricing Rule (But will it Survive?)

Source: 
FDA Law Blog
snippet: 

A flourish of drug regulatory actions have issued from the Trump Administration during its waning days.  Within the past two weeks, HHS has terminated FDA’s Unapproved Drug Initiative by withdrawing two guidances, finalized a proposed OIG safe harbor regulation on PBM rebates that HHS had earlier withdrawn, and revived a CMS rulemaking proceeding to establish international reference pricing under Medicare.